Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo

Open access
Jackaman, Connie, Majewski, David, Fox, Simon A., Nowak, Anna K., Nelson, Delia J. · 2012 · Cancer Immunology, Immunotherapy

Abstract

Cytotoxic chemotherapies may expose the immune system to high levels of tumor antigens and expand the CD8(+) T-cell response to include weak or subdominant antigens. Here, we evaluated the in vivo CTL response to tumor antigens using a murine mesothelioma tumor cell line transfected with a neotumor antigen, ovalbumin, that contains a known hierarchy of epitopes for MHC class I molecules. We show that as tumors progress, effector CTLs are generated in vivo that focus on the dominant epitope SIINFEKL, although a weak response was seen to one (KVVRFDKL) subdominant epitope. These CTLs did not prevent tumor growth. Cisplatin treatment slowed tumor growth, slightly improved in vivo SIINFEKL presentation to T cells and reduced SIINFEKL-CTL activity. However, the CTL response to KVVRFDKL was amplified, and a response to another subdominant epitope, NAIVFKGL, was revealed. Similarly, gemcitabine cured most mice, slightly enhanced SIINFEKL presentation, reduced SIINFEKL-CTL activity yet drove a significant CTL response to NAIVFKGL, but not KVVRFDKL. These NAIVFKGL-specific CTLs secreted IFNγ and proliferated in response to in vitro NAIVFKGL stimulation. IL-2 treatment during chemotherapy refocused the response to SIINFEKL and simultaneously degraded the cisplatin-driven subdominant CTL response. These data show that chemotherapy reveals weaker tumor antigens to the immune system, a response that could be rationally targeted. Furthermore, while integrating IL-2 into the chemotherapy re…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00262-012-1307-4

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Research works printed but not linked: 4

  1. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295–3301 · DOI
  2. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180:1471–1483 · DOI · Paper page
  3. Lipford GB, Hoffman M, Wagner H, Heeg K (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150:1212–1222 · DOI
  4. Grufman P, Wolpert EZ, Sandberg JK, Karre K (1999) T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol 29:2197–2204 · doi:10.1002/(sici)1521-4141(199907)29:07<2197::aid-immu2197>3.0.co;2-b

Cited by

See all 105

Metadata

Authors
Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J.
Affiliations
  • Curtin University (AU)
  • The University of Western Australia (AU)
Corresponding author
Nelson, Delia J.
Venue
Cancer Immunology, Immunotherapy
Published
2012-06-20
Volume
61
Issue
12
Pages
2343-2356
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2078500268
Cited by
105
References
47
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 16 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 6 · 2016: 6 · 2015: 1 · 2014: 4 · 2013: 5
FWCI
1.40
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • eSpace (Curtin University) (submittedVersion)
Funders
  • University of Queensland
  • Curtin University of Technology
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
chemotherapy, tumor antigens, CD8+ cytotoxic T lymphocytes, subdominant epitopes, mesothelioma, ovalbumin, SIINFEKL, cisplatin, gemcitabine, interleukin-2, interferon-gamma, tumor immunology, cancer immunotherapy
MeSH terms
Gemcitabine, Animals, Epitopes, Antigens, Neoplasm, Antineoplastic Agents, Cisplatin, Cytotoxicity, Immunologic, Deoxycytidine, Female, Interferon-gamma, Interleukin-2, Mesothelioma, Mice, Inbred C57BL, Ovalbumin, T-Lymphocytes, Cytotoxic, Transfection, Histocompatibility Antigens Class I, Antigen Presentation, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo. https://app.cochat.ai/papers/10.1007/s00262-012-1307-4
The paper
Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J. (2012). Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-012-1307-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.